Precision Medicine and Immunotherapy in GI Cancers
Authors: Eileen M. O'Reilly, Andrew H. Ko
Journal: Journal of Clinical Oncology (2022)

Article Tools OVERVIEWS Special Series: Precision Medicine and Immunotherapy in GI Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.22.00601 Journal of Clinical Oncology - published online before print July 15, 2022 PMID: 35839433 Precision Medicine and Immunotherapy in GI Cancers Eileen M. O'Reilly , MD1,2xEileen M. O'ReillySearch for articles by this author and Andrew H. Ko, MD3xAndrew H. KoSearch for articles by this author Show More 1Memorial Sloan Kettering Cancer Center, New York, NY2Weill Cornell Medical College, New York, NY3University of California San Francisco, San Francisco, CA https://doi.org/10.1200/JCO.22.00601 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsAdministrative support: Eileen M. O'ReillyCollection and assembly of data: Eileen M. O'ReillyManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTPrecision Medicine and Immunotherapy in GI CancersThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Eileen M. O'ReillyThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Adicet Bio, AstraZeneca, Alnylam, Autem Medical, BeiGene, Berry Genomics, CytomX Therapeutics, Eisai, Exelixis, Genentech/Roche, Genoscience Pharma, Helio Health, Incyte, Ipsen, Legend Biotech, Merck, Nerviano Medical Sciences, QED Therapeutics, RedHill Biopharma, Yiviva, Novartis, Rafael Pharmaceuticals, Seattle Genetics, Boehringer Ingelheim, IDEAYA Biosciences, Noxxon Pharma, BioSapien, Thetis Pharma, Cend Therapeutics, Flatiron HealthResearch Funding: AstraZeneca/MedImmune (Inst), Celgene (Inst), Genentech (Inst), Roche (Inst), Silenseed (Inst), Arcus Ventures (Inst), BioNTech (Inst), Elicio Therapeutics (Inst), Parker Institute for Cancer Immunotherapy (Inst)Andrew H. KoThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Honoraria: Research to Practice, Clinical Care Options, PER, PlatformQ Health, Medscape, BioAscentConsulting or Advisory Role: ERYTECH Pharma, Imugene, SynCoreBio, Gritstone Bio, Roche/Genentech, Ipsen, Five Prime Therapeutics, Tyme, Turning Point Therapeutics, Signatera, Syros PharmaceuticalsSpeakers' Bureau: Clinical Care OptionsResearch Funding: Celgene (Inst), Merck (Inst), Genentech/Roche (Inst), Bristol Myers Squibb (Inst), AbGenomics International (Inst), Apexigen (Inst), Astellas Pharma (Inst), Leap Therapeutics (Inst)No other potential conflicts of interest were reported.